



IFW

PATENT

Customer No. 22,852

Attorney Docket No. 07680.0018-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Seng H. Cheng *et al.*) Group Art Unit: 1632
)
Application No.: 10/758,773) Examiner: Not yet assigned
)
Filed: January 16, 2004)
)
For: Combination Enzyme) Confirmation No.: 6298
Replacement, Gene Therapy and)
Small Molecule Therapy For)
Lysosomal Storage Diseases)

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed is the following:

- 1) Information Disclosure Statement Under 37 C.F.R. § 1.97(B), and
- 2) PTO Form 1449.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated:

6/21/04

By:

E. Stewart Mittler
Reg. No. 50,316



PATENT
Customer No. 22,852
Attorney Docket No. 07680.0018-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Seng H. Cheng <i>et al.</i>)	Group Art Unit: 1632
)	
Application No.: 10/758,773)	Examiner: Not yet assigned
)	
Filed: January 16, 2004)	
)	
For: Combination Enzyme)	Confirmation No.: 6298
Replacement, Gene Therapy and)	
Small Molecule Therapy For)	
Lysosomal Storage Diseases)	

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of all listed documents, except U.S. patents, were submitted in prior U.S. Application No. 09/884,526.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine

that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated:

6/21/04

By:




E. Stewart Mittler
Reg. No. 50,316

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	07680.0018-00000	Appln. No.	10/758,773
Applicant	Seng H. Cheng and David Meeker		
Filing Date	January 16, 2004	Group:	1632

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	6,066,626	05/23/00	Yew et al.	514	44	
	5,916,911	06/29/99	Shayman et al.	514	428	
	5,945,442	08/31/99	Shayman et al.	514	428	
	5,952,370	09/14/99	Shayman et al.	514	428	
	6,030,995	02/29/00	Shayman et al.	514	428	
	6,040,332	03/21/00	Shayman et al.	514	428	
	6,051,598	04/18/00	Shayman et al.	514	428	
	5,840,702	11/24/98	Bedwell	514	23	
	6,696,059	06/24/04	Jacob et al.	424	94.61	
	6,495,570	12/17/02	Jacob et al.	514	328	
	20030017139	01/23/03	Souza et al.	424	93.3	05/06/02
	20020142985		Dwek et al.	514	44	10/19/01
	20010044453		Jacob et al.	514	320	05/17/01
	20020127213		Jacob et al.	424	94.1	01/22/02

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
WO 00/09153	02/24/00	PCT			
WO 00/62779	10/26/00	PCT			
WO 00/62780	10/26/00	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Abe et al., "Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation," J. Clin. Invest. 105:563, 2000.
Abe et al., "Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase," Kidney International 57:446, 2000.
Cox et al., "Novel oral treatment of Gaucher disease with N-leutyldeoxynojirimycin (06T 918) to decrease substrate biosynthesis," Lancet 355:1481, 2000.
Deonarain et al., Exp. Opin. Ther. Patents, 8(1):53,1998.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	07680.0018-00000	Appln. No.	10/758,773
Applicant	Seng H. Cheng and David Meeker		
Filing Date	January 16, 2004	Group:	1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Desnick et al., "Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy," <i>Annals Int. Med.</i> 138:338, 2003.
	Eck et al., Goodman and Gilman's <i>The Pharmacological Basis of Therapeutics</i> , Ninth Edition, McGraw-Hill, New York, 1996, p 77-101.
	Eng et al., "Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease," <i>N. Engl. J. Med.</i> 345:9, 2001.
	Gorecki, <i>Expert Opin. Emerging Drugs</i> , 6(2):187.
	Ioannou et al., "Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice," <i>Am. J. Hum. Genet.</i> 68:14, 2001.
	Jeyakumar et al., "Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin," <i>Proc. Natl. Acad. Sci. USA</i> 96:6388, 1999.
	Jung et al., "Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice," <i>Proc. Natl. Acad. Sci. USA</i> 98:2676.
	Kakkis et al., "Overexpression of the human lysosomal enzyme alpha-L-iduronidase in Chinese hamster ovary cells," <i>Prot. Express. Purif.</i> 5:225, 1994.
	Kakkis et al., "Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I," <i>Biochem. Molec. Med.</i> 58:156, 1996.
	Keeling et al., "Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation," <i>Hum. Molec. Genet.</i> 10:291, 2001.
	Kikuchi et al., "Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail," <i>J. Clin. Invest.</i> 101:827, 1998.
	Lee et al., "Improved inhibitors of glucosylceramide synthase," <i>J. Biol. Chem.</i> 274:14662, 1999.
	Medin et al., "Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector," <i>Proc. Natl. Acad. Sci. USA</i> 93:7917, 1996.
	Neufeld et al., "Lysosomal storage diseases," <i>Annu. Rev. Biochem.</i> 60:257, 1991.
	Oshima et al., "Cloning, sequencing, and expressin of cDNA for human beta-glucuronidase," <i>Proc. Natl. Acad. Sci. USA</i> 81:685, 1987.
	Overkleeft et al., "Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase," <i>J. Biol. Chem.</i> 273(41):26522, 1998.
	Park et al., "Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer," <i>Proc. Natl. Acad. Sci. USA</i> 100:3450, 2003.
	Pauly et al., "Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle," <i>Gene Therapy</i> 5:473, 1998.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	07680.0018-00000	Appln. No.	10/758,773
Applicant	Seng H. Cheng and David Meeker		
Filing Date	January 16, 2004	Group:	1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Platt et al., "Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin," Science 276:428, 1997.
	Ponce et al., "Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase," Blood 90:43, 1997.
	Schiffmann et al., "Enzyme replacement therapy in Fabry disease: a randomized controlled trial," JAMA 285:2743, 2001.
	Schiffmann et al., "Infusion of alpha-galactosidase A reduces tissue globotriasylceramide storage in patients with Fabry disease," Proc. Natl. Acad. Sci. USA, 97(1):365, 2000.
	Shayman et al., "Inhibitors of glucosylceramide synthase," Meth. Enzymol. 311:373, 2000.
	Shull et al., "Enzyme replacement in a canine model of Hurler syndrome," Proc. Natl. Acad. Sci. USA 91:12937, 1998.
	Takahashi et al., "E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor," Mol. Ther. 5:627, 2002.
	Van Der Ploeg et al., "Breakdown of lysosomal glycogen in cultured fibroblasts from glycogenosis type II patients after uptake of acid alpha-glucosidase," J. Neurolog. Sci. 79:327, 1987.
	Van Der Ploeg, et al., "Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice," J. Clin. Invest. 87:513, 1991.
	Van Der Ploeg et al., "Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells," J. Neurol. 235:392, 1998.
	Van Der Ploeg et al., "Receptor-mediated uptake of acid alpha-glucosidase corrects lysosomal glycogen storage in cultured skeletal muscle," Pediatr. Res. 24:90, 1988.
	Van Hove et al., "High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease," Proc. Natl. Acad. Sci. USA 93:65, 1996.
	Zaretsky et al., "Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion," Human Gene Therapy 8:1555, 1997.
	Ziegler et al., "Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease," Human Gene Ther. 13:935, 2002.
	Ziegler et al., "Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer," Human Gene Ther. 10:1667, 1999.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	07680.0018-00000	Appln. No.	10/758,773
Applicant	Seng H. Cheng and David Meeker		
Filing Date	January 16, 2004	Group:	1632

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce